The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Yuchen Guo,
Chu Lin,
Xiaoling Cai,
Han Wu,
Jingya Yan,
Zonglin Li,
Ruoyang Jiao,
Shuzhen Bai,
Wenjia Yang,
Fang Lv,
Geling Liu,
Xiaolin Yang,
Linong Ji
Affiliations
Yuchen Guo
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Chu Lin
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Xiaoling Cai
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China; Corresponding author
Han Wu
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Jingya Yan
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Zonglin Li
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Ruoyang Jiao
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Shuzhen Bai
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Wenjia Yang
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Fang Lv
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China
Geling Liu
Department of Endocrinology and Metabolism (Section 1), Tangshan Gongren Hospital, No. 27 Wenhua Road, Tangshan, Hebei 063000, P.R. China
Xiaolin Yang
Department of Endocrinology and Metabolism (Section 1), Tangshan Gongren Hospital, No. 27 Wenhua Road, Tangshan, Hebei 063000, P.R. China
Linong Ji
Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11, Xizhimen South Street, Xicheng District, Beijing 100044, P.R. China; Corresponding author
Summary: The association between anti-obesity medications (AOMs) as well as their weight-loss effects and cardiovascular outcomes need to be comprehensively investigated. We searched PubMed, Embase, the Cochrane Center Register of Controlled Trials for Studies, and Clinicaltrial.gov website from the inception to April 2024 and included 129 randomized controlled trials (RCTs) of AOMs. When compared with placebo, every 5 kg weight reduction mediated by AOMs was associated with the reduced risks of 3-point major adverse cardiovascular events (relative risk [RR] 0.72, 95% confidence interval [CI] 0.60–0.85), myocardial infarction (RR 0.75, 95% CI 0.60–0.95), stroke (RR 0.60, 95% CI 0.42–0.85), and heart failure (RR 0.71, 95% CI 0.54–0.95). As for glucagon-like peptide 1 receptor agonist (GLP-1RA)-users, similar cardiovascular benefits were also observed with 5 kg weight loss. This study indicated that the weight reductions mediated by AOMs were associated with cardiovascular benefits observed in AOM-users.
